Organogenesis Hldgs Inc Financials
This page shows Organogenesis Hldgs Inc (ORGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Organogenesis Hldgs Inc has an operating margin of 7.9%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 40/100, indicating healthy but not exceptional operating efficiency. This is up from -0.3% the prior year.
Organogenesis Hldgs Inc's revenue surged 17.0% year-over-year to $564.2M, reflecting rapid business expansion. This strong growth earns a score of 62/100.
Organogenesis Hldgs Inc carries a low D/E ratio of 0.99, meaning only $0.99 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.62, Organogenesis Hldgs Inc holds $3.62 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 71/100.
While Organogenesis Hldgs Inc generated -$10.3M in operating cash flow, capex of $14.2M consumed most of it, leaving -$24.5M in free cash flow. This results in a low score of 14/100, reflecting heavy capital investment rather than weak cash generation.
Organogenesis Hldgs Inc's ROE of 12.3% shows moderate profitability relative to equity, earning a score of 39/100. This is up from 0.3% the prior year.
Organogenesis Hldgs Inc scores 2.29, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Organogenesis Hldgs Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Organogenesis Hldgs Inc generates $-0.28 in operating cash flow (-$10.3M OCF vs $37.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Organogenesis Hldgs Inc earns $19.6 in operating income for every $1 of interest expense ($44.7M vs $2.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Organogenesis Hldgs Inc generated $564.2M in revenue in fiscal year 2025. This represents an increase of 17.0% from the prior year.
Organogenesis Hldgs Inc's EBITDA was $60.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 386.0% from the prior year.
Organogenesis Hldgs Inc reported $37.0M in net income in fiscal year 2025. This represents an increase of 4201.0% from the prior year.
Organogenesis Hldgs Inc earned $0.15 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1600.0% from the prior year.
Cash & Balance Sheet
Organogenesis Hldgs Inc generated -$24.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 685.7% from the prior year.
Organogenesis Hldgs Inc held $93.7M in cash against $0 in long-term debt as of fiscal year 2025.
Organogenesis Hldgs Inc had 127M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.
Margins & Returns
Organogenesis Hldgs Inc's operating margin was 7.9% in fiscal year 2025, reflecting core business profitability. This is up 8.2 percentage points from the prior year.
Organogenesis Hldgs Inc's net profit margin was 6.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.4 percentage points from the prior year.
Organogenesis Hldgs Inc's ROE was 12.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 12.0 percentage points from the prior year.
Capital Allocation
Organogenesis Hldgs Inc invested $44.5M in research and development in fiscal year 2025. This represents a decrease of 11.4% from the prior year.
Organogenesis Hldgs Inc invested $14.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 41.1% from the prior year.
ORGO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $225.6M+49.5% | $150.9M+49.4% | $101.0M+16.5% | $86.7M-31.6% | $126.7M+10.0% | $115.2M-11.6% | $130.2M+18.4% | $110.0M |
| Cost of Revenue | N/A | N/A | N/A | $23.7M-23.6% | $31.1M+15.9% | $26.8M-8.2% | $29.2M+1.7% | $28.7M |
| Gross Profit | N/A | N/A | N/A | $63.0M-34.1% | $95.6M+8.2% | $88.4M-12.5% | $101.0M+24.3% | $81.3M |
| R&D Expenses | $10.3M-22.2% | $13.2M+27.2% | $10.4M-2.3% | $10.6M-7.7% | $11.5M+11.5% | $10.3M-33.6% | $15.6M+21.7% | $12.8M |
| SG&A Expenses | $100.2M+25.6% | $79.7M+8.0% | $73.8M+1.8% | $72.5M-1.8% | $73.9M+2.9% | $71.8M-6.2% | $76.5M+5.8% | $72.3M |
| Operating Income | $63.3M+205.3% | $20.7M+264.8% | -$12.6M+53.0% | -$26.7M-361.7% | $10.2M+63.7% | $6.2M+144.9% | -$13.9M-260.6% | -$3.9M |
| Interest Expense | -$236K+43.1% | -$415K+38.0% | -$669K+30.4% | -$961K-1475.4% | -$61K-113.0% | $471K-24.0% | $620K+20.6% | $514K |
| Income Tax | $19.7M+4946.9% | -$407K+83.3% | -$2.4M+64.8% | -$6.9M-369.0% | $2.6M+139.6% | -$6.5M-360.0% | $2.5M+211.6% | -$2.2M |
| Net Income | $43.7M+102.6% | $21.6M+329.6% | -$9.4M+50.2% | -$18.8M-345.6% | $7.7M-37.8% | $12.3M+172.4% | -$17.0M-711.6% | -$2.1M |
| EPS (Diluted) | N/A | $0.11+210.0% | $-0.10+41.2% | $-0.17 | N/A | $0.09+169.2% | $-0.13-550.0% | $-0.02 |
ORGO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $598.7M+17.4% | $509.8M+10.6% | $461.1M-1.3% | $467.4M-6.1% | $497.9M+11.6% | $446.3M+0.7% | $443.2M-3.3% | $458.5M |
| Current Assets | $362.2M+20.8% | $299.7M+15.2% | $260.2M-3.0% | $268.2M-6.2% | $285.9M+19.9% | $238.5M+1.8% | $234.2M+3.1% | $227.2M |
| Cash & Equivalents | $93.7M+47.0% | $63.7M-12.8% | $73.1M-33.5% | $110.0M-18.9% | $135.6M+43.7% | $94.3M+4.9% | $89.9M+1.4% | $88.6M |
| Inventory | $29.6M-25.2% | $39.6M+19.8% | $33.0M+12.6% | $29.3M+11.9% | $26.2M-3.0% | $27.0M+0.6% | $26.9M-2.9% | $27.7M |
| Accounts Receivable | $217.5M+28.8% | $168.8M+40.2% | $120.4M+16.5% | $103.3M-6.0% | $109.9M+8.5% | $101.3M-4.4% | $105.9M+10.2% | $96.1M |
| Goodwill | $28.8M0.0% | $28.8M0.0% | $28.8M0.0% | $28.8M0.0% | $28.8M0.0% | $28.8M0.0% | $28.8M0.0% | $28.8M |
| Total Liabilities | $298.6M+17.2% | $254.7M+11.8% | $227.9M+1.5% | $224.5M-4.5% | $235.0M+40.1% | $167.7M-6.6% | $179.7M-0.4% | $180.5M |
| Current Liabilities | $100.1M+10.9% | $90.3M+37.2% | $65.8M+1.2% | $65.1M-16.0% | $77.5M+0.3% | $77.3M-9.9% | $85.7M+3.5% | $82.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $62.3M-2.2% | $63.8M-2.2% | $65.2M |
| Total Equity | $300.1M+17.6% | $255.1M+9.4% | $233.2M-4.0% | $242.9M-7.6% | $262.9M-5.6% | $278.5M+5.7% | $263.5M-5.2% | $278.0M |
| Retained Earnings | -$3.1M+93.4% | -$46.8M+31.6% | -$68.3M-15.9% | -$59.0M-47.0% | -$40.1M+16.1% | -$47.8M+20.5% | -$60.1M-39.6% | -$43.1M |
ORGO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $39.4M+1180.3% | $3.1M+109.4% | -$32.9M-64.9% | -$19.9M-282.3% | $10.9M+25.8% | $8.7M+83.5% | $4.7M+146.6% | -$10.2M |
| Capital Expenditures | $4.7M+108.1% | $2.2M-38.6% | $3.6M+0.3% | $3.6M+7.9% | $3.4M+30.8% | $2.6M+36.6% | $1.9M-15.4% | $2.2M |
| Free Cash Flow | $34.8M+4019.4% | $844K+102.3% | -$36.5M-55.0% | -$23.6M-411.0% | $7.6M+23.7% | $6.1M+114.3% | $2.9M+123.1% | -$12.4M |
| Investing Cash Flow | -$4.7M-108.1% | -$2.2M+38.6% | -$3.6M-0.3% | -$3.6M-7.9% | -$3.4M-30.8% | -$2.6M-36.6% | -$1.9M+15.4% | -$2.2M |
| Financing Cash Flow | -$4.8M+52.9% | -$10.2M-3444.1% | -$288K+86.0% | -$2.1M-106.1% | $33.6M+2106.5% | -$1.7M+2.9% | -$1.7M+33.8% | -$2.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ORGO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | 72.6%-2.8pp | 75.5%-1.2pp | 76.7%-0.9pp | 77.6%+3.7pp | 73.9% |
| Operating Margin | 28.1%+14.3pp | 13.7%+26.2pp | -12.4%+18.4pp | -30.9%-38.9pp | 8.1%+2.6pp | 5.4%+16.1pp | -10.7%-7.2pp | -3.5% |
| Net Margin | 19.4%+5.1pp | 14.3%+23.6pp | -9.3%+12.4pp | -21.7%-27.8pp | 6.1%-4.7pp | 10.7%+23.8pp | -13.1%-11.2pp | -1.9% |
| Return on Equity | 14.6%+6.1pp | 8.5%+12.5pp | -4.0%+3.7pp | -7.8%-10.7pp | 2.9%-1.5pp | 4.4%+10.9pp | -6.5%-5.7pp | -0.8% |
| Return on Assets | 7.3%+3.1pp | 4.2%+6.3pp | -2.0%+2.0pp | -4.0%-5.6pp | 1.5%-1.2pp | 2.8%+6.6pp | -3.9%-3.4pp | -0.5% |
| Current Ratio | 3.62+0.3 | 3.32-0.6 | 3.95-0.2 | 4.12+0.4 | 3.69+0.6 | 3.09+0.4 | 2.73-0.0 | 2.74 |
| Debt-to-Equity | 0.990.0 | 1.00+0.0 | 0.98+0.1 | 0.92+0.0 | 0.89+0.7 | 0.22-0.0 | 0.240.0 | 0.23 |
| FCF Margin | 15.4%+14.8pp | 0.6%+36.7pp | -36.1%-9.0pp | -27.2%-33.2pp | 6.0%+0.7pp | 5.3%+3.1pp | 2.2%+13.5pp | -11.3% |
Similar Companies
Frequently Asked Questions
What is Organogenesis Hldgs Inc's annual revenue?
Organogenesis Hldgs Inc (ORGO) reported $564.2M in total revenue for fiscal year 2025. This represents a 17.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Organogenesis Hldgs Inc's revenue growing?
Organogenesis Hldgs Inc (ORGO) revenue grew by 17% year-over-year, from $482.0M to $564.2M in fiscal year 2025.
Is Organogenesis Hldgs Inc profitable?
Yes, Organogenesis Hldgs Inc (ORGO) reported a net income of $37.0M in fiscal year 2025, with a net profit margin of 6.6%.
What is Organogenesis Hldgs Inc's EBITDA?
Organogenesis Hldgs Inc (ORGO) had EBITDA of $60.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Organogenesis Hldgs Inc's operating margin?
Organogenesis Hldgs Inc (ORGO) had an operating margin of 7.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Organogenesis Hldgs Inc's net profit margin?
Organogenesis Hldgs Inc (ORGO) had a net profit margin of 6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Organogenesis Hldgs Inc's return on equity (ROE)?
Organogenesis Hldgs Inc (ORGO) has a return on equity of 12.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Organogenesis Hldgs Inc's free cash flow?
Organogenesis Hldgs Inc (ORGO) generated -$24.5M in free cash flow during fiscal year 2025. This represents a -685.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Organogenesis Hldgs Inc's operating cash flow?
Organogenesis Hldgs Inc (ORGO) generated -$10.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Organogenesis Hldgs Inc's total assets?
Organogenesis Hldgs Inc (ORGO) had $598.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Organogenesis Hldgs Inc's capital expenditures?
Organogenesis Hldgs Inc (ORGO) invested $14.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Organogenesis Hldgs Inc spend on research and development?
Organogenesis Hldgs Inc (ORGO) invested $44.5M in research and development during fiscal year 2025.
What is Organogenesis Hldgs Inc's current ratio?
Organogenesis Hldgs Inc (ORGO) had a current ratio of 3.62 as of fiscal year 2025, which is generally considered healthy.
What is Organogenesis Hldgs Inc's debt-to-equity ratio?
Organogenesis Hldgs Inc (ORGO) had a debt-to-equity ratio of 0.99 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Organogenesis Hldgs Inc's return on assets (ROA)?
Organogenesis Hldgs Inc (ORGO) had a return on assets of 6.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Organogenesis Hldgs Inc's cash runway?
Based on fiscal year 2025 data, Organogenesis Hldgs Inc (ORGO) had $93.7M in cash against an annual operating cash burn of $10.3M. This gives an estimated cash runway of approximately 109 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Organogenesis Hldgs Inc's Altman Z-Score?
Organogenesis Hldgs Inc (ORGO) has an Altman Z-Score of 2.29, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Organogenesis Hldgs Inc's Piotroski F-Score?
Organogenesis Hldgs Inc (ORGO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Organogenesis Hldgs Inc's earnings high quality?
Organogenesis Hldgs Inc (ORGO) has an earnings quality ratio of -0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Organogenesis Hldgs Inc cover its interest payments?
Organogenesis Hldgs Inc (ORGO) has an interest coverage ratio of 19.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Organogenesis Hldgs Inc?
Organogenesis Hldgs Inc (ORGO) scores 51 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.